By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics today announced it is terminating its agreement to buy RedPath Integrated Pathology, following a decision by Medicare to limit its coverage for RedPath's portfolio of tests only to its pancreatic test.

The decision comes after ExonHit and RedPath were unable to agree on revised terms and conditions following the decision by Medicare contractor Highmark Medicare Services to cover only RedPath's TG-Pancreatic cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.